Top Story Today
Sanofi and Regeneron Bet $8 Billion That Their Best Work Isn't Behind Them
The longest-running partnership in pharma just got bigger. Sanofi is paying $1 billion upfront (with up to $7 billion more in milestones) to add four next-generation antibodies to its Regeneron alliance, all targeting the same inflammatory pathways that made Dupixent a $17.8 billion-a-year juggernaut. The new molecules are designed to be long-acting successors that could replace Dupixent across its sprawling list of indications before patent expiry hits. It's the biotech equivalent of recording your follow-up album while your current single is still topping the charts.
Why it matters: With Dupixent's eventual loss of exclusivity threatening a multi-billion-dollar revenue hole for both companies, this deal is an insurance policy built on nearly two decades of shared immunology conviction, and a signal that next-gen antibody science still commands serious capital.
Read more →Clinical Wins and Misses
BioNTech's mRNA Cancer Vaccine Misses in Phase 2/3 Head and Neck Trial
The COVID-to-cancer mRNA narrative just took a hit. BioNTech's BNT113 failed to improve progression-free survival in head and neck cancer when added to Merck's pembrolizumab, missing the phase 2/3 co-primary endpoint. The trial continues toward an overall survival readout, but with Moderna already posting a Phase 3 win in melanoma, the mRNA oncology scoreboard reads Moderna 1, BioNTech 0.
Read more →BMS's Radioactive Sniper Rifle Nails Phase 3 in Rare Digestive Tumors
Bristol Myers Squibb's $4.1 billion RayzeBio acquisition just produced its first payoff. Alpha-emitting radiopharmaceutical RYZ101 hit its primary endpoint in GEP-NET patients who had already failed Novartis's Lutathera, validating the idea that swapping beta radiation for alpha particles makes a clinically meaningful difference. Detailed data (hazard ratios, medians) are still under wraps.
Read more →BMS's Lung Scarring Drug Passed Its Test, Then Things Got Complicated
Admilparant became the first LPA1 antagonist to hit a Phase 3 endpoint in IPF, with the 60 mg dose preserving lung function over 52 weeks. But the higher 120 mg dose missed statistical significance, and a patient death from multi-organ failure in that arm (judged "unlikely related") adds a safety asterisk. Expect the 60 mg dose to anchor any regulatory filing.
Read more →The Obesity Arms Race
Novo Pays $300 Million for an Obesity Pill That Hasn't Touched a Human
Novo Nordisk dropped $300 million upfront (up to $2.6 billion total) on Hengrui's HRS-1596, a once-weekly oral GLP-1/GIP pill that's only phase 1-ready. With Eli Lilly's oral orforglipron already approved, Novo is paying a premium for optionality in the race to replace injections with pills. The deal needs U.S. antitrust clearance before closing.
Read more →Roche Bets $1.16 Billion on a Fat Gene Silencer
Roche signed a deal worth up to $1.16 billion with China's Rona Therapeutics for an RNAi-based obesity drug that silences the ALK7 gene in fat tissue. The approach could selectively burn visceral fat while preserving muscle, addressing the biggest knock on current GLP-1 drugs. It's the latest in Roche's multi-billion-dollar obesity shopping spree targeting top-three status by 2030.
Read more →Regulatory and Safety Watch
Daiichi Sankyo and Merck Pull Their Own FDA Application Before Rejection
Daiichi Sankyo and Merck voluntarily withdrew the application for their ADC ifinatamab deruxtecan in small cell lung cancer. The Phase 2 data (48.2% response rate) wasn't robust enough for accelerated approval. A Phase 3 trial continues, but this is the first real stumble for the companies' $22 billion ADC partnership.
Read more →Former FDA Regulator Calls for Withdrawal of Only Prader-Willi Hunger Drug
Seven deaths and nearly 100 hospitalizations have been reported since Vykat XR's approval for Prader-Willi syndrome, prompting a former FDA official to publicly call for its removal. For families who waited decades for any treatment targeting the disorder's relentless hunger, losing the only approved option would be devastating. The FDA has tools between "do nothing" and "pull the plug"; expect tighter monitoring first.
Read more →